Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 16/20 | 0.86 |
| ▸ | CDK8 | P49336 | 16/20 | 0.86 |
| ▸ | CDK19 | Q9BWU1 | 16/20 | 0.86 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7447024 | 0.81 | CCNC (0.78) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL6978646 | 0.75 | CCNC (0.59) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL6976237 | 0.71 | CCNC (0.55) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL6978882 | 0.71 | CCNC (0.55) | CCNCCDK8CDK19CDK9GAA | |
| SCHEMBL18429198 | 0.71 | CCNC (1.00) | CCNCCDK8CDK19CDK9 | |
| SCHEMBL6990670 | 0.71 | CCNC (0.60) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL6967359 | 0.70 | CCNC (0.56) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL7241443 | 0.70 | CCNC (1.00) | CCNCCDK8CDK19CDK9 | |
| SCHEMBL6977569 | 0.70 | CCNC (0.53) | CCNCCDK8CDK19CDK9ALDH1A1 | |
| SCHEMBL6980131 | 0.69 | CCNC (0.55) | CCNCCDK8CDK19CDK9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | claimed |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| JP-2000239280-A | TRICYCLIC THIOPHENE COMPOUND | TAISHO PHARMACEUT CO LTD | 2000-09-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | CCNC 2012/4885CDK8 3614/4885CDK19 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.